Patents Assigned to ARCUS BIOSCIENCES, INC.
  • ANTI-CD39 ANTIBODIES AND USE THEREOF
    Publication number: 20250084178
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Application
    Filed: March 25, 2024
    Publication date: March 13, 2025
    Applicants: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, Jijie Gu
  • Inhibitors of ARG1 and/or ARG2
    Patent number: 12226425
    Abstract: Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: February 18, 2025
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Beatty, Eric Thomas Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Corinne Nicole Foley, Rebecca Louise Grange, Tezcan Guney, Steven Donald Jacob, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal
  • Compounds as inhibitors of AXL
    Patent number: 12195482
    Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.
    Type: Grant
    Filed: August 14, 2024
    Date of Patent: January 14, 2025
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
  • Azolopyrimidine for the treatment of cancer-related disorders
    Patent number: 12195447
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: January 14, 2025
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
  • CBL-B INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250011318
    Abstract: Disclosed herein are compounds having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: May 24, 2024
    Publication date: January 9, 2025
    Applicant: ARCUS BIOSCIENCES, INC.
    Inventors: Srikanth Kumar Gangam, Clayton Hardman, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Artur Karenovich Mailyan, Masa Podunavac, Shiwei Qu, Zhang Wang, Xianglin Yin, Kai Yu, Tzu-Yu Yu
  • COMPOUNDS AS INHIBITORS OF AXL
    Publication number: 20240425526
    Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.
    Type: Application
    Filed: August 14, 2024
    Publication date: December 26, 2024
    Applicant: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
  • Cbl-b Inhibitors and Methods of Use Thereof
    Publication number: 20240425497
    Abstract: Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: May 3, 2024
    Publication date: December 26, 2024
    Applicant: ARCUS BIOSCIENCES, INC.
    Inventors: Srikanth Kumar Gangam, Clayton Hardman, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Artur Karenovich Mailyan, Masa Podunavac, Shiwei Qu, Xianglin Yin, Kai Yu, Tzu-Yu Yu
  • Inhibitors of adenosine 5?-nucleotidase
    Patent number: 12168023
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: April 8, 2024
    Date of Patent: December 17, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Process for preparing tetralin compounds
    Patent number: 12145901
    Abstract: The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: November 19, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Fournier, Balint Gal, Karl T. Haelsig, Clayton Hardman, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Artur Karenovich Mailyan, Guillaume Mata, Brandon Reid Rosen, Zhang Wang, Kai Yu
  • Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
    Patent number: 12103907
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: October 1, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
  • Inhibitors of HIF-2? and methods of use thereof
    Patent number: 12071411
    Abstract: The present disclosure is directed to compounds that are inhibitors of HIF-2? having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: August 27, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Fournier, Balint Gal, Clayton Hardman, Artur Karenovich Mailyan, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Guillaume Mata, Ma{hacek over (s)}a Podunavac, Jay Patrick Powers, Brandon Reid Rosen, Kai Yu
  • Pyridone A2R antagonists
    Patent number: 12064433
    Abstract: Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: August 20, 2024
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Manmohan Reddy Leleti, Debashis Mandal, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan U I Sharif
  • Arginase inhibitors
    Patent number: 12054500
    Abstract: Compounds that are inhibitors of at least one of the ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: August 6, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Corinne Nicole Foley, Rebecca Louise Grange, Tezcan Guney, Jaroslaw Kalisiak, Eric Thomas Newcomb, Anh Thu Tran
  • Solid forms of an azolopyrimidine compound
    Patent number: 11993584
    Abstract: The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile (Compound I), and methods of making and using the same.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 28, 2024
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Jenna Leigh Jeffrey, Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers
  • Anti-CD39 antibodies and use thereof
    Patent number: 11970543
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: April 30, 2024
    Assignees: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, JijIe Gu
  • INHIBITORS OF HPK1 AND METHODS OF USE THEREOF
    Publication number: 20240124490
    Abstract: Disclosed herein are compounds that are Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 18, 2024
    Applicant: Arcus Biosciences, Inc.
    Inventors: Joshua R. Corbin, Sandeep Dhanju, Corinne Nicole Foley, Jeremy Fournier, Padmanabha V. Kattamuri, Manmohan Reddy Leleti, Pradeep Nareddy, Jay Patrick Powers, Ehesan Ul Sharif, Joice Thomas
  • CD73 inhibitors
    Patent number: 11931343
    Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: March 19, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Beatty, Laurent Pierre Paul Debien, Samuel Lawrie Drew, Jeremy Fournier, Rebecca Louise Grange, Steven Donald Jacob, Jenna Leigh Jeffrey, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal, Jay Patrick Powers, Anh Thu Tran, Rhiannon Thomas-Tran, Xuelei Yan
  • ANTI-CD39 ANTIBODIES AND USE THEREOF
    Publication number: 20240034803
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Application
    Filed: March 2, 2023
    Publication date: February 1, 2024
    Applicants: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, Jijie Gu
  • Solid forms of a CD73 inhibitor and the use thereof
    Patent number: 11819512
    Abstract: Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein. The use of such solid form of Compound I and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 21, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Jenna Leigh Jeffrey, Kenneth V. Lawson, Dillon Harding Miles
  • Antibodies to TIGIT
    Patent number: 11820824
    Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: November 21, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Kelsey Sivick Gauthier, Nigel Pelham Clinton Walker, Xiaoning Zhao, John Lippincott